| Literature DB >> 33313325 |
Nina C B B Veiby1, Aida Simeunovic2,3,4,5, Martin Heier3,5, Cathrine Brunborg6, Naila Saddique1, Morten C Moe1,4, Knut Dahl-Jørgensen3,4,5, Hanna D Margeirsdottir3,5, Goran Petrovski1,4.
Abstract
METHODS: OCTA of both eyes was performed in a cross-sectional study of 14 to 30-year-old individuals with at least 10-year duration of T1D and controls recruited from the Norwegian Atherosclerosis and Childhood Diabetes (ACD) study. Vessel density (VD) and foveal avascular zone (FAZ) area in the superficial and deep capillary plexus (SCP and DCP), total retinal volume (TRV), and central macular thickness (CMT) were calculated using automated software. Univariate and multivariate ordered logistic regression (OLR) models were used accordingly.Entities:
Mesh:
Year: 2020 PMID: 33313325 PMCID: PMC7721511 DOI: 10.1155/2020/8849116
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1OCTA scans from two control eyes. This illustrates how the FAZ area is delineated and how different the size and shape can be in normal eyes. (a) The FAZ is 0.04 mm2 in the SCP, and crossing capillaries in the FAZ area makes it difficult to decide where to measure. (b) The FAZ is 0.58 mm2 in the SCP.
Figure 2Representative 3 × 3 mm macular OCTA scans of the SCP and DCP for each ICDR level of NPDR in T1D patients. It is visible that the FAZ area increases and the vessel density decreases due to capillary dropout with the increasing level of NPDR. There are also some visible microaneurisms (arrows).
Demographic and clinical characteristics of study patients (n = 254 individuals).
| ICDR level in patients with type 1 diabetes | ||||||||
|---|---|---|---|---|---|---|---|---|
| Controls | All T1D | NDR | Mild NPDR | Moderate NPDR | Severe NPDR |
|
| |
| Gender male/female (male %) | 41/47 (46.6%) | 68/98 (41%) | 48/65 (42.5%) | 17/23 (42.5%) | 3/8 (27.3%) | 0/2 (0%) | ||
| Age (years) | 23.9 ± 3.4 | 24.3 ± 3.3 | 23.5 ± 3.4 | 25.3 ± 2.2 | 27.1 ± 1.9 | 27.6 ± 0.9 | <0.001 | 0.471 |
| Age onset of diabetes (years) | 8.6 ± 3.4 | 8.8 ± 3.4 | 8.6 ± 3.1 | 7.3 ± 4.1 | 4.7 ± 2.5 | 0.222 | ||
| Duration of diabetes (years) | 15.7 ± 3.8 | 14.8 ± 3.5 | 16.7 ± 3.3 | 19.8 ± 4.2 | 23.0 ± 1.7 | <0.001 | ||
| Mean arterial blood pressure (mmHg) | 85.9 ± 8.0 | 89.6 ± 8.0 | 89.1 ± 8.7 | 89.9 ± 5.5 | 93.0 ± 7.2 | 89.5 ± 0.23 | 0.473 | 0.001 |
| Body mass index | 23.6 ± 3.1 | 25.7 ± 4.5 | 25.2 ± 3.6 | 25.2 ± 4.8 | 31.2 ± 7.8 | 28.8 ± 0.02 | <0.001 | <0.001 |
| Waist circumference (cm) | 80.5 ± 10.0 | 85.2 ± 12.3 | 83.2 ± 9.7 | 86.3 ± 12.6 | 99.3 ± 22.7 | 98.7 ± 8.9 | <0.001 | 0.002 |
| Serum glucose (mmol/L) | 4.8 ± 0.4 | 10.0 ± 4.3 | 9.9 ± 4.3 | 10.1 ± 4.1 | 9.9 ± 4.6 | 14.8 ± 5.8 | 0.462 | <0.001 |
| HbA1C (mmol/mol) | 32.2 ± 2.9 | 64.9 ± 15.5 | 64.1 ± 15.3 | 65.3 ± 10.8 | 70.3 ± 27.1 | 78.1 ± 24.7 | 0.357 | <0.001 |
| Hemoglobin (g/dL) | 14.4 ± 1.2 | 14.5 ± 1.2 | 14.4 ± 1.2 | 14.5 ± 1.3 | 15.2 ± 1.0 | 14.4 ± 0.0 | 0.590 | 0.535 |
| Total cholesterol (mmol/L) | 4.4 ± 0.7 | 4.5 ± 0.9 | 4.5 ± 0.9 | 4.3 ± 0.8 | 4.8 ± 1.0 | 4.6 ± 1.5 | 0.405 | 0.289 |
| HDL cholesterol (mmol/L) | 1.6 ± 0.4 | 1.6 ± 0.4 | 1.6 ± 0.4 | 1.5 ± 0.4 | 1.6 ± 0.6 | 1.8 ± 0.01 | 0.776 | 0.516 |
| LDL cholesterol (mmol/L) | 2.7 ± 0.7 | 2.8 ± 0.7 | 2.8 ± 0.7 | 2.6 ± 0.7 | 3.0 ± 0.7 | 2.6 ± 1.5 | 0.419 | 0.275 |
| Triglycerides (mmol/L) | 0.87 ± 0.4 | 1.01 ± 0.8 | 0.97 ± 0.9 | 1.04 ± 0.7 | 1.38 ± 0.9 | 0.85 ± 0.1 | 0.474 | 0.080 |
| U-albumin-creatinine ratio (mg/mmol) | 3.7 ± 17.0 | 1.0 ± 2.2 | 1.0 ± 2.4 | 1.0 ± 1.4 | 1.6 ± 1.6 | 1.4 ± 0.8 | 0.831 | 0.154 |
| BCVA LogMAR right eye | −0.07 ± 0.07 | −0.05 ± 0.07 | −0.05 ± 0.07 | −0.06 ± 0.06 | −0.03 ± 0.11 | 0.00 ± 0.00 | 0.406 | 0.019 |
| BCVA LogMAR left eye | −0.07 ± 0.08 | −0.05 ± 0.07 | −0.06 ± 0.07 | −0.04 ± 0.07 | −0.05 ± 0.09 | −0.03 ± 0.06 | 0.420 | 0.014 |
| IOP right eye (mmHg) | 14.5 ± 2.7 | 16.1 ± 3.2 | 16.1 ± 3.4 | 16.5 ± 2.8 | 15.4 ± 3.8 | 17.7 ± 0.6 | 0.635 | <0.001 |
| IOP left eye (mmHg) | 14.1 ± 3.0 | 15.9 ± 3.4 | 15.7 ± 3.5 | 16.2 ± 2.9 | 16.1 ± 4.3 | 17.7 ± 1.5 | 0.595 | <0.001 |
| Spherical equivalent, refraction right eye (diopters) | −0.37 ± 1.44 | −1.03 ± 1.57 | −0.98 ± 1.69 | −1.12 ± 1.14 | −1.39 ± 1.73 | 0.00 ± 0.71 | 0.651 | 0.001 |
| Spherical equivalent, refraction left eye (diopters) | −0.33 ± 1.50 | −0.98 ± 1.48 | −0.92 ± 1.55 | −1.07 ± 1.17 | −1.41 ± 1.83 | −0.13 ± 0.18 | 0.592 | 0.001 |
| MOPP (mmHg) | 42.8 ± 5.4 | 43.6 ± 5.8 | 43.4 ± 6.5 | 43.4 ± 3.9 | 46.7 ± 5.2 | 42.2 ± 0.5 | 0.341 | 0.316 |
Values are mean ± SD. ∗p value: independent sample t-test for difference between all T1D and controls. ⱡp value: global one-way ANOVA analysis for the difference between the NPDR subgroups.
Descriptive analysis of macular OCTA parameters in controls and patients with T1D with different levels of NPDR.
| NPDR level in patients with type 1 diabetes | |||||||
|---|---|---|---|---|---|---|---|
| OCTA parameters | Controls | NDR | Mild NPDR | Moderate | Severe NPDR |
|
|
|
| |||||||
| FAZ area in SCP (mm2) | 0.26 ± 0.09 (0.05-0.59) | 0.25 ± 0.10 (0.04-0.56) | 0.28 ± 0.12 (0.09-0.81) | 0.29 ± 0.15 (0.08-0.70) | 0.77 ± 0.58 (0.29-1.42) |
|
|
| FAZ area in DCP (mm2) | 0.35 ± 0.09 (0.13-0.61) | 0.33 ± 0.11 (0.07-0.72) | 0.34 ± 0.12 (0.16-0.79) | 0.39 ± 0.16 (0.18-0.73) | 0.83 ± 0.55 (0.34-1.43) |
|
|
| Vessel density in SCP (%) | 17.98 ± 3.52 (10.78-26.44) | 16.57 ± 3.53 (9.78-28.78) | 17.02 ± 2.86 (11.56-25.00) | 16.94 ± 2.22 (13.67-22.33) | 18.15 ± 0.34 (17.78-18.44) |
|
|
| Vessel density in DCP (%) | 38.55 ± 1.83 (32.00-42.33) | 36.60 ± 2.49 (30.00-42.44) | 35.53 ± 1.92 (29.89-39.56) | 33.23 ± 2.91 (29.22-38.44) | 27.89 ± 2.79 (26.22-31.11) |
|
|
|
| |||||||
| Total retinal volume, TRV (mm3) | 9.54 ± 0.34 (8.80-10.26) | 9.41 ± 0.42 (8.33-10.84) | 9.52 ± 0.32 (8.25-10.14) | 9.4 ± 0.40 (8.64-9.97) | 9.01 ± 0.41 (8.69-9.47) |
|
|
| Central macular thickness, CMT ( | 272.74 ± 16.33 (229-309) | 269.13 ± 19.80 (212-315) | 269.50 ± 19.69 (232-321) | 267.53 ± 28.9 (225-310) | 244.67 ± 23.67 (231-272) |
|
|
Values are mean ± SD (range). n = eyes. ∗p value: independent sample t-test for the difference between controls and T1D eyes with no NPDR (NDR). ⱡp value: global one-way ANOVA analysis for the difference between all the NPDR subgroups.
Figure 3Vessel density in the deep capillary plexus is decreasing with the increasing level of NPDR. Post hoc pairwise comparison between all the subgroups after one-way ANOVA analysis shows a significant difference in vessel density between each level of NPDR.
Association between clinical risk factors and OCTA parameters in T1D patients without retinopathy vs. controls calculated by GEE analysis.
| Univariable model | Multivariable model | Final model | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
|
| ||||||
| Gender | 1.06 (0.83-1.35) | 0.643 | ||||
| Age (years) | 0.99 (0.95-1.03) | 0.542 | ||||
| Mean arterial blood pressure (mmHg) | 1.03 (1.01-1.05) | <0.001 | 1.03 (1.01-1.06) | 0.015 | 1.03 (1.01-1.06) | 0.007 |
| Waist circumference (cm) | 1.00 (1.01-1.03) | 0.002 | 1.01 (0.99-1.03) | 0.384 | ||
| Hemoglobin pr SD (g/dL) | 1.26 (0.51-3.13) | 0.617 | ||||
| Serum glucose (mmol/L) | 1.78 (1.57-2.03) | <0.001 | 1.74 (1.52-1.98) | <0.001 | 1.75 (1.53-1.99) | <0.001 |
| Total cholesterol (mmol/L) | 1.13 (0.97-1.13) | 0.112 | ||||
| HDL cholesterol (mmol/L) | 0.90 (0.67-1.21) | 0.498 | ||||
| LDL cholesterol (mmol/L) | 1.16 (0.97-1.38) | 0.085 | ||||
| Triglycerides (mmol/L) | 1.15 (0.95-1.40) | 0.157 | ||||
| U-albumin-creatinine ratio (mg/mmol) | 0.98 (0.95-1.01) | 0.116 | ||||
| Spherical equivalent (diopters) | 0.84 (0.77-0.92) | <0.001 | 0.90 (0.78-1.04) | 0.144 | ||
| Best-corrected visual acuity pr SD | 1.18 (1.03-1.36) | 0.020 | 1.09 (0.92-1.28) | 0.315 | ||
|
| ||||||
| FAZ area in SCP pr SD (mm2) | 0.88 (0.75-1.04) | 0.133 | ||||
| FAZ area in DCP pr SD (mm2) | 0.86 (0.73-1.01) | 0.070 | ||||
| Vessel density in SCP (%) | 0.93 (0.90-0.97) | <0.001 | 0.93 (0.88-0.99) | 0.014 | 0.92 (0.87-0.97) | 0.002 |
| Vessel density in DCP (%) | 0.78 (0.73-0.83) | <0.001 | 0.84 (0.76-0.92) | <0.001 | 0.83 (0.7-0.90) | <0.001 |
|
| ||||||
| Total retinal volume (mm3) | 0.59 (0.43-0.82) | 0.002 | 0.73 (0.40-1.32) | 0.294 | ||
| Central macular thickness ( | 0.99 (0.98-1.00) | 0.044 | 1.00 (0.99-1.01) | 0.931 | ||
The associations of clinical risk factors and OCTA parameters with the increasing level of NPDR calculated as odds ratios with ordered logistic regression analysis.
| Univariable model | Multivariable model | Final model | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| OR (95% CI) |
| |
|
| ||||||
| Gender | 2.51 (0.62-10.2) | 0.198 | ||||
| Age (years) | 1.90 (1.39-2.60) | <0.001 | 1.31 (0.99-1.74) | 0.061 | ||
| Duration of diabetes (years) | 1.74 (1.36-2.22) | <0.001 | 1.38 (1.11-1.73) | 0.004 | 1.51 (1.22-1.87) | <0.001 |
| Mean arterial blood pressure (mmHg) | 1.06 (0.97-1.15) | 0.182 | ||||
| Body mass index | 1.24 (1.05-1.48) | 0.014 | ||||
| Waist circumference (cm) | 1.12 (1.05-1.20) | 0.001 | 1.07 (1.01-1.13) | 0.014 | 1.08 (1.02-1.14) | 0.005 |
| HbA1C (mmol/mol) | 1.57 (0.96-2.56) | 0.070 | ||||
| Serum glucose (mmol/L) | 1.06 (0.90-1.25) | 0.456 | ||||
| Hemoglobin pr SD (g/dL) | 1.26 (0.51-3.13) | 0.617 | ||||
| Total cholesterol (mmol/L) | 0.98 (0.46-2.09) | 0.967 | ||||
| HDL cholesterol (mmol/L) | 0.92 (0.18-4.82) | 0.920 | ||||
| LDL cholesterol (mmol/L) | 0.81 (0.32-2.06) | 0.659 | ||||
| Triglycerides (mmol/L) | 1.74 (0.78-3.89) | 0.180 | ||||
| U-albumin-Creatinine ratio (mg/mmol) | 1.13 (0.84-1.51) | 0.295 | ||||
| Spherical equivalent (diopters) | 0.90 (2.29-1.37) | 0.619 | 0.98 (0.65-1.48) | 0.913 | 0.86 (0.58-1.29) | 0.477 |
| Best-corrected visual acuity pr SD | 2.29 (1.11-4.71) | 0.025 | 1.59 (0.83-3.02) | 0.159 | ||
| IOP (mmHg) | 1.08 (0.89-1.30) | 0.443 | ||||
|
| ||||||
| FAZ area in SCP pr SD (mm2) | 1.83 (0.96-3.50) | 0.068 | ||||
| FAZ area in DCP pr SD (mm2) | 1.67 (0.89-3.12) | 0.108 | ||||
| Vessel density in SCP (%) | 1.10 (0.93-1.30) | 0.258 | ||||
| Vessel density in DCP (%) | 0.55 (0.44-0.71) | <0.001 | 0.67 (0.52-0.85) | 0.001 | 0.65 (0.51-0.83) | <0.001 |
|
| ||||||
| Total retinal volume, TRV (mm3) | 0.92 (0.18-4.77) | 0.925 | ||||
| Central macular thickness, CMT ( | 0.98 (0.95-1.02) | 0.367 | ||||